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This article presents an Executive Summary of the conclusions and recommendations of the 10-chapter
TFOS DEWS II report. The entire TFOS DEWS II report was published in the July 2017 issue of The Ocular
Surface. A downloadable version of the document and additional material, including videos of diagnostic
and management techniques, are available on the TFOS website: www.TearFilm.org.
© 2017 Elsevier Inc. All rights reserved.1. Introduction
Dry eye disease (DED) affects hundreds of millions of people
throughout the world and is one of the most frequent causes of
patient visits to eye care practitioners. It is a symptomatic disease,
characterized by a vicious cycle of tear ﬁlm instability and hyper-
osmolarity, which leads to increased ocular surface inﬂammation,
damage and neurosensory abnormalities. Moderate to severe DED
is associated with signiﬁcant pain, limitations in performing dailynstitute, 20 Staniford Street,
du (D.A. Sullivan).activities, reduced vitality, poor general health, and often
depression.
To increase our understanding of DED, the Tear Film & Ocular
Surface Society (TFOS), a non-proﬁt organization, launched the
TFOS Dry Eye Workshop II (TFOS DEWS II) in March 2015 [1]. This
initiative reﬂected the TFOS mission, which is to advance the
research, literacy, and educational aspects of the scientiﬁc ﬁeld of
the tear ﬁlm and ocular surface. The goal of the TFOS DEWS II was to
achieve a global consensus concerning multiple aspects of DED.
More speciﬁcally, TFOS DEWS II sought to: 1) Update the deﬁnition
and classiﬁcation of DED; 2) Evaluate critically the epidemiology,
pathophysiology, mechanism, and impact of this disorder; 3)
Develop recommendations for the diagnosis, management and
therapy of this disease; and 4) Recommend the design of clinical
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The TFOS DEWS II involved the efforts of 150 clinical and basic
science research experts from around the world, who utilized an
evidence-based approach and a process of open communication,
dialogue and transparency to increase our understanding of DED.
This process required more than 2 years to complete.
The entire TFOS DEWS II report was published in the July 2017
issue of The Ocular Surface. A downloadable version of the docu-
ment and additional material, including videos of diagnostic
and management techniques, are available on the TFOS website:
www.TearFilm.org. It is anticipated that translations of the report
will be offered in many languages, including, but not limited to,
Chinese, French, German, Italian, Japanese, Korean, Polish, Portu-
guese, Romanian, Spanish, Turkish and Vietnamese. These trans-
lations, when completed, will be available on the TFOS website.
An Executive Summary of the conclusions and recommenda-
tions of the TFOS DEWS II report is presented in this article. The
material is abstracted from the reports of ten TFOS DEWS II Sub-
committees, which were Deﬁnition and Classiﬁcation; Epidemi-
ology; Sex, Gender, and Hormones; Pathophysiology; Tear Film;
Iatrogenic Dry Eye; Pain and Sensation; Diagnostic Methodology;
Management and Therapy; and Clinical Trial Design. Additional
details and all references can be obtained in the open access, online
version.
2. Deﬁnition and classiﬁcation [2]
The goals of the TFOS DEWS II Deﬁnition and Classiﬁcation
Subcommittee were to create an evidence-based deﬁnition and a
contemporary classiﬁcation system for DED. The new deﬁnition is
as follows:
“Dry eye is a multifactorial disease of the ocular surface char-
acterized by a loss of homeostasis of the tear ﬁlm, and accom-
panied by ocular symptoms, in which tear ﬁlm instability and
hyperosmolarity, ocular surface inﬂammation and damage, and
neurosensory abnormalities play etiological roles.”
The terminology in this deﬁnition, including diction, word order,
emphasis, and accepted meaning, was critical in creating an inter-
nationally accepted deﬁnition. The term “multifactorial disease”
recognizes DED as a signiﬁcant and complex, functional disorder
that cannot be characterized by a single process, sign or symptom.
The term “ocular surface” is deﬁned as comprising the structures of
the ocular surface and adnexa, including the tear ﬁlm, lacrimal and
meibomian glands, cornea, conjunctiva and eyelids. “Homeostasis”
describes a state of dynamic equilibrium in the bodywith respect to
its various functions, and to the chemical composition of the ﬂuids
and tissues. Disruption of homeostasis is considered to be the
unifying characteristic that encompasses the myriad of signs of tear
ﬁlm and ocular surface imbalance that might be observed in DED.
The term “symptoms” embraces a broad range of possible patient-
reported experiences associated with DED including, but not
limited to, discomfort and visual disturbance. The key elements
contributing to the pathophysiological process, including tear ﬁlm
instability, hyperosmolarity, inﬂammation and damage, recognized
as etiological triggers of the vicious circle, were deemed important,
along with neurosensory abnormalities, which have featured
increasingly in the recent literature, for inclusion in the deﬁnition.
In the classiﬁcation of DED, the latest evidence supports a
scheme based on its pathophysiology in which aqueous deﬁcient
dry eye (ADDE) and evaporative dry eye (EDE) exist as a continuum,
such that elements of each need to be considered in diagnosis and
management. This approach is not intended to override clinical
assessment and judgment but to help guide clinical managementand future research.
The Subcommittee's recommended classiﬁcation of DED is
shown in Fig. 1. The upper portion of the ﬁgure represents a clinical
decision algorithm, beginning with the assessment of symptoms,
and followed by review for signs of ocular surface disease. DED
exhibits both symptoms and signs, and can be differentiated from
other ocular surface disease with the use of triaging questions and
ancillary testing. It is to this DED group that diagnostic subtyping,
and conventional DEDmanagement strategies, apply. Symptomatic
patients without demonstrable clinical signs do not fall into the
DED group, but are differentiated into pre-clinical ocular surface
disease or neuropathic pain (non-ocular surface disease).
Conversely, asymptomatic patients exhibiting signs are differenti-
ated into patients with poor corneal sensitivity, or those with
prodromal signs, who may be at risk of developing manifest DED
with time or provocation, for example following ophthalmic sur-
gery or contact lens ﬁtting. Finally, the option exists for patients
without either signs or symptoms to be classiﬁed, according to the
ﬂow chart, as ‘normal’.
The lower portion of Fig. 1 represents the etiological classiﬁca-
tion of DED, and highlights the two predominant and non-mutually
exclusive categories; ADDE and EDE. Epidemiological and clinical
evidence suggest that the preponderance of DED is evaporative in
nature, which is reﬂected by devotion of a greater proportion of
Fig. 1 to EDE than to ADDE. While it is possible that ADDE can occur
without obvious signs of EDE and vice versa, as DED progresses, it is
increasingly likely that characteristics of both ADDE and EDE will
become evident. Further subclassiﬁcation of ADDE and EDE is not
detailed in Fig. 1, but is acknowledged to relate to a vast range of
conditions, as described in the TFOS DEWS II Pathophysiology
report. ADDE describes conditions affecting lacrimal gland func-
tion. EDE is recognized to include both lid-related (for example,
meibomian gland dysfunction [MGD] and blink-related) and ocular
surface-related (such as mucin and contact lens-related) causes.
3. Epidemiology [3]
The TFOS DEWS II Epidemiology report examines literature on
the prevalence, incidence, risk factors, natural history, and
morbidity and reviewed questionnaires used in epidemiological
studies of DED. The report focuses on epidemiological studies
published since the previous TFOS DEWS report in 2007. A meta-
analysis of all published prevalence data was undertaken to esti-
mate the impact of age (Table 1) and sex on symptoms and signs of
DED. Global mapping of DED prevalence was undertaken using
geospatial analysis. The report summarizes the available evidence
on the epidemiology of DED and provides recommendations for
future needs and opportunities.
DED epidemiology continues to be challenged by the failure for
a standardized deﬁnition and diagnostic criteria to be used.
Consequently, the report describes prevalence based on commonly
used diagnostic criteria, including those based on symptoms, on
self-report of a practitioner diagnosis, and on DED signs.
While much new information has been published in the last
10 years, no population studies have reported on prevalence of
DED for populations south of the equator. Much of the attention
has focused on Asia and Europe. The prevalence of DED, with and
without symptoms, ranged in prevalence from 5 to 50%. DED
prevalence based on signs alone was generally higher and more
variable, reaching up to 75% in some populations. Criteria for
positive DED signs varied between studies and it was acknowl-
edged that some signs may reﬂect secondary outcomes or may be
related to normal aging. Very few studies were conducted in
younger populations (less than 40 years of age) but indications
are that DED is also prevalent in these populations. The evidence
Fig. 1. DED classiﬁcation scheme. Please see the original report for a complete description of this ﬁgure [2].
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consistent.
The meta-analysis conﬁrmed that symptomatic disease and
signs of DED increase with age, however prevalence of signs
showed a greater increase per decade than symptomatic disease.
Higher rates of DED are reported in women than men, although
the differences generally become signiﬁcant only with increasing
age.
Risk factors were categorised as consistent, probable, and
inconclusive, in line with the previous TFOS DEWS report [4]. Age,
sex, race, MGD, connective tissue disease, Sj€ogren syndrome,
androgen deﬁciency, computer use, contact lens wear, estrogen
replacement therapy, hematopoietic stem cell transplantation,
certain environmental conditions (such as pollution, low humid-
ity, and sick building syndrome) and medication use (for example,
antihistamines, antidepressants, anxiolytics, and isotretinoin)
were identiﬁed as consistent risk factors. Probable risk factors
included diabetes, rosacea, viral infection, thyroid disease, psy-
chiatric conditions, pterygium, low fatty acid intake, refractive
surgery, allergic conjunctivitis, and additional medications (e.g.
anti-cholinergic, diuretics, b-blockers). Inconclusive DED risks are
Hispanic ethnicity, menopause, acne, sarcoidosis, smoking,
alcohol, pregnancy, demodex infestation, botulinum toxin injec-
tion, multivitamins and oral contraceptives.The economic burden on society and impact of DED on the in-
dividual, through its detrimental effect on vision, quality of life, and
work productivity, as well as the psychological and physical impact
of pain, are considerable. The most signiﬁcant costs are indirect
costs due to reduced work productivity. Questionnaires used to
evaluate DED vary in their utility for epidemiological studies and
further evidence for normative ranges and clinically signiﬁcant
changes are required.
Future research needs include better evaluation of the preva-
lence of DED of varying severity and in youth, the incidence of
disease in different populations, and the impact of modiﬁable risk
factors such as mobile device usage. Geographical mapping ap-
proaches will further allow the impact of climate, environment and
socioeconomic factors on DED to be elucidated. There has been
limited study of the natural history of both treated and untreated
DED and this remains an important area for future research.4. Sex, gender, and hormones [5]
One of the most compelling features of DED is that it occurs
more frequently in women than in men. In fact, the female sex is a
signiﬁcant risk factor for the development of DED. That such a sex-
related variation exists in the prevalence of an eye disease, or any
other ocular function, should not be a surprise, as sex-related
Table 1
Regression analysis of prevalence data by age for each diagnostic subgroup.
Diagnostic subgroup N of studies Slope estimate (per decade of age) Std error of slope estimate p-value (H0: slope ¼ 0) R2
1. Symptoms or OSDI  23 8 3.43 0.57 0.001 0.858
2. Self-report of a clinician diagnosis of dry eye 8 2.01 0.73 0.034 0.556
3. WHS Criteria 8 0.44 0.57 0.475a 0.088
b4. Schirmer 5 10.55 1.78 0.010 0.921
b5. Tear break up time 5 9.71 1.20 0.004 0.956
b6. Corneal staining 5 7.63 1.67 0.020 0.875
b7. MGD 5 5.23 1.44 0.036 0.815
OSDI -Ocular SurfaceDisease Index;WHS-Women'sHealth Study;MGD -meibomianglanddysfunction. Please see theoriginal report for a completedescriptionof thisﬁgure [3].
a Indicates that there is no change in prevalence by age for the WHS criteria.
b Regression analyses are based on estimates of prevalence from age 40e49 and beyond (i.e., missing values for prevalence for ages 15e18, 19e29, and 30e39).
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of the body. Indeed, since 1945, more than 575,000 scientiﬁc re-
ports have been published which address the basic and/or clinical
impact of sex on human physiology and pathophysiology.
The TFOS DEWS II Sex, Gender, and Hormones report details
numerous sex-related differences that have been identiﬁed in the
eye. Many of these differences have been attributed to the effects of
sex steroids (e.g. androgens and estrogens), hypothalamic-pituitary
hormones, glucocorticoids, insulin, insulin-like growth factor 1 and
thyroid hormones. For example, androgens are extremely impor-
tant in the regulation of the ocular surface and adnexa. They appear
to mediate many of the sex-related differences in these tissues.
Androgen deﬁciency, in turn, predisposes to lacrimal gland
dysfunction, serves as a risk factor for MGD, and is associated with
the development of both ADDE and EDE. In contrast to androgens,
the role of estrogens at the ocular surface is less well deﬁned, with
effects that appear to be sex-, tissue-, and dose-speciﬁc.
In addition, sex-related differences may arise from the sex
chromosome complement, including differences in parent-of-
origin effects, X chromosome gene dosage (e.g. X-inactivation)
and genes in the non-recombining region of the Y chromosome, as
well as from sex-speciﬁc autosomal factors and epigenetics (e.g.
microRNAs, DNA methylation and acetylation, histone
modiﬁcations).
It is important to note that the word “sex” is used for a reason.
Although “sex” and “gender” are often used interchangeably, they
have distinct meanings. As stated in a 2001 report by the Institute
of Medicine [6], “sex” refers to the classiﬁcation of living things,
generally as male or female, according to their reproductive organs
and functions assigned by chromosomal complement. “Gender”
refers to a person's self-representation as a man or woman, or how
social institutions respond to that person based on the individual's
gender presentation. Gender is rooted in biology, but is shaped by
environment and experience. In other words, sex distinguishes
males and females based on their biological characteristics. Gender,
in turn, reﬂects socially constructed characteristics such as behav-
iors and expectations related to being a man, masculine, or being a
woman, feminine. Furthermore, gender is dynamic, context-related
and operates on a spectrum.
In effect, both sex and gender affect health and disease, as well
as patients' perceptions about their health. Gender also affects in-
dividuals' access to and interactions with the health care system.
Many health disparities are associated with gender. Disparities
arise from a range of inﬂuences that are biological, behavioral/
perceptual, cultural, and societal. Therefore, both sex and gender-
dterms that are distinguishable, but intertwined, should be
considered, as they both have pronounced effects on health and on
health disparities. Gender and biological sex affect DED risk, pre-
sentation of the disease, immune responses, pain, care-seeking
behaviors, service utilization, and a myriad of other facets of eye
health.Overall, sex, gender and hormones play a major role in the
regulation of ocular surface and adnexal tissues, and in the differ-
ence in DED prevalence between women and men.
5. Pathophysiology [7]
On the basis of peer-reviewed literature, the TFOS DEWS II
Pathophysiology Subcommittee concluded that the core mecha-
nism of DED is evaporation-induced tear hyperosmolarity, which is
the hallmark of the disease. It damages the ocular surface both
directly and by initiating inﬂammation. The cycle of events,
described as the Vicious Circle of DED, is shown at the center of
Fig. 2.
Two forms of DED are recognized, ADDE and EDE. In ADDE, tear
hyperosmolarity results when lacrimal secretion is reduced, in
conditions of normal evaporation from the eye. In EDE, tear
hyperosmolarity is caused by excessive evaporation from the
exposed tear ﬁlm in the presence of a normally functioning lacrimal
gland. Since tear osmolarity is a function of tear evaporation in
either ADDE or EDE, tear hyperosmolarity arises due to evaporation
from the ocular surface and, in that sense, all forms of DED are
evaporative. In other words, EDE is more accurately considered a
hyper-evaporative state.
In DED, tear hyperosmolarity is considered to be the trigger for a
cascade of signaling events within surface epithelial cells, which
leads to the release of inﬂammatory mediators and proteases. Such
mediators, together with the tear hyperosmolarity itself, are un-
derstood to cause goblet cell and epithelial cell loss and damage to
the epithelial glycocalyx. Inﬂammatory mediators from activated T-
cells, recruited to the ocular surface, reinforce damage. The net
result is the characteristic punctate epitheliopathy of DED and a
tear ﬁlm instability which leads at some point to early tear ﬁlm
breakup. This breakup exacerbates and ampliﬁes tear hyper-
osmolarity and completes the vicious circle events that lead to
ocular surface damage. Ultimately this is thought to lead to self-
perpetuation of the disease.
Tear ﬁlm instability can be initiated without the prior occur-
rence of tear hyperosmolarity, by conditions that affect the ocular
surface, including xerophthalmia, ocular allergy, topical preserva-
tive use and contact lenswear. In this case, early tear ﬁlm breakup is
hypothesized to be the primary basis for tear ﬁlm hyperosmolarity
initially experienced locally at the site of breakup, and with
increasing severity, at some point becoming detectable in tear
meniscus samples. This represents an ocular surfaceerelated form
of EDE. In MGD-related EDE tear hyperosmolarity results from a
tear ﬁlm lipid layer deﬁciency. In ADDE the onset of early breakup
during the evolution of the disease, may add a secondary evapo-
rative element to the DED.
There are various causes of ADDE. It may result from blocking
the sensory drive to the lacrimal gland that is essential to maintain
tear ﬁlm homeostasis. Bilateral topical anesthesia can cause both a
Fig. 2. Pathophysiology of DED. Please see the original report for a complete description of this ﬁgure [7].
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reﬂex tearing can be caused by chronic abuse of topical anesthetics,
trigeminal nerve damage and refractive surgery including LASIK
surgery. The delivery of aqueous tears to the tear sac can also be
reduced by obstruction to the lacrimal ducts, which might occur in
any form of cicatricial conjunctival disease, such as trachoma,
ocular cicatricial pemphigoid, erythema multiforme, graft-versus-
host-disease and chemical burns. A number of drugs in systemic
use, such as antihistamines, b-blockers, antispasmodics, diuretics
and some psychotropic drugs, can cause a reduction in lacrimal
secretion and are risk factors for DED [3,8]. Also, tear secretion rate
falls in later life.
In the Western world the most common cause of ADDE is in-
ﬂammatory inﬁltration of the lacrimal gland, encountered most
severely in the DED associated with autoimmune disorders such as
Sj€ogren syndrome (SSDE) and, with lesser severity, in non-Sj€ogren
syndrome (NSDE). Inﬂammation causes both acinar and ductal
epithelial cell dysfunction and/or destruction and a potentially
reversible neurosecretory block. Circulating antibodies to the
muscarinic (M3) receptor may also cause a receptor block. Low
tissue androgen levels may predispose to lacrimal gland
inﬂammation.
Epithelial injury and defective glycocalyx, loss of tear volume
and of goblet cell mucin, lead to increased frictional damage and
friction-related symptoms. The tear hyperosmolarity and epithelial
injury caused by DED stimulates corneal nerve endings, leading to
symptoms of discomfort, increased blink rate and potentially, to a
compensatory, reﬂex increase in lacrimal tear secretion. This
compensatory secretion is more likely in EDE, where lacrimal gland
function is potentially normal.
A schematic diagram to show the etiology and mechanism of
MGD, which is the major cause of EDE, is shown in Fig. 3. Althoughmany mechanistic aspects are not yet understood, the ﬁgure at-
tempts to summarize the current view. The upper part of the ﬁgure
illustrates the etiology of the two forms of MGD that result in low
delivery of meibum, cicatricial and non-cicatricial MGD.
With age, there is an increase in meibomian gland dropout,
particularly after the age of 50 years, which correlates with the
appearance of primary MGD. A fall in bioavailable androgens may
contribute to these events. In youth, treatment of acne vulgaris
with cis-retinoic acid may induce gland atrophy and MGD, while in
an older age group, androgen receptor insensitivity or blockade
may induce signs of MGD. The anti-glaucoma drugs pilocarpine and
timolol also have direct effects on human meibomian gland
epithelial cells that may inﬂuence their morphology, survival and/
or proliferative capacity, and possibly promote MGD. Poly-
chlorinated biphenyls may cause a systemic disorder that includes
MGD-like features. Certain skin disorders, such as acne rosacea,
atopic dermatitis, seborrheic dermatitis and psoriasis are associ-
ated with non-cicatricial MGD, while cicatricial conjunctival dis-
eases such as trachoma, erythema multiforme and pemphigoid,
lead to cicatricial MGD.
A key event in non-cicatricial MGD is hyperkeratinization of
the terminal ducts, leading to duct obstruction, duct dilatation
and disuse atrophy of the glands. Later, obliteration of the gland
oriﬁces may occur. Obstruction may be exacerbated by changes in
oil composition that increase meibum viscosity. The degree to
which inﬂammatory changes are found around affected glands
varies in different reports, but signs of inﬂammation are common
at the lid margin. Inﬂammatory mediators and lipids may be
released into tears and onto the ocular surface to cause epithelial
damage. In cicatricial MGD, submucosal conjunctival scarring
drags the meibomian oriﬁces, terminal ducts and mucocutaneous
junction posteriorly, across the posterior lid border and onto the
Fig. 3. Pathophysiology of MGD. Please see the original report for a complete description of this ﬁgure [7].
J.P. Craig et al. / The Ocular Surface 15 (2017) 802e812 807tarsal plate, where the narrowed and displaced ducts can no
longer deliver meibum effectively to the tear ﬁlm lipid layer. Low
meibum delivery and changes in oil composition can lead to tear
ﬁlm instability, increased tear evaporation and ultimately to EDE.
In low delivery MGD, symptoms may arise from the local lid dis-
ease itself, from lid disease with ocular surface damage and from
EDE.6. Tear ﬁlm [8]
The TFOS DEWS II Tear Film Subcommittee recommended a
two-phasemodel of the tear ﬁlm, which has a lipid layer overlying a
muco-aqueous phase. Wax and cholesteryl esters (non-polar lipids)
make up the majority of the tear lipid layer and these are spread
onto the muco-aqueous layer by an underlying layer of polar lipids,
including (O-acyl)-u-hydroxy fatty acids and possibly phospho-
lipids. The role of the tear ﬁlm lipid layer alone in preventing
evaporation and breakup of tears on the eye is controversial. It is
likely that interactions of the whole tear ﬁlm, including lipids,
mucins, proteins and salts, prevent evaporation and collapse, but
further work is needed to conﬁrm this together with the relative
roles of the various components.
Several studies have attempted to correlate changes in tear lipid
biochemistry with DED, but no deﬁnitive linkage has yet been
made. In contrast, tear osmolarity received considerable attention
as the hallmark of DED, increasing with the severity of DED.
The muco-aqueous layer overlies the apical epithelial cells and
their carbohydrate-rich glycocalyx. Changes in the amount of
mucin or the glycosylation of different components have been re-
ported in tears collected from DED patients. The muco-aqueous
layer contains at least four major mucins, and over 1500 differentproteins and peptides. Tear proteins have been reported to differ in
tears from DED subjects, but no deﬁnitive set of proteins or their
degrees of change are yet validated to aid diagnosis. This is an area
that should receive increased attention.
Changes to the tear ﬁlm clearly occur in DED. However, the lack
of uniﬁed clinical parameters in tear ﬁlm studies and the relatively
limited understanding of the structure of the tear ﬁlm has
hampered comprehension of how these changes occur and their
signiﬁcance in the pathophysiology of DED. Improvements in the
ability to characterize the biochemistry of the tear ﬁlm may lead to
the identiﬁcation of new markers that can be used to diagnose,
potentially predict, and even treat DED. A holistic approach to
understanding tear ﬁlm structure and function will undoubtedly
lead to better treatments for patients with this disease.7. Pain and sensation [9]
As noted by the TFOS DEWS II Pain & Sensation Subcommittee,
pain can be differentiated into nociceptive and neuropathic types.
Nociceptive pain occurs in response to actual or threatened damage
to tissues. However, neuropathic pain occurs due to a lesion within
the somatosensory nervous system and is commonly referred to as
pathologic pain or pain without biological value.
Pain associatedwith DED is transmitted via the peripheral axons
of trigeminal ganglion (TG) neurons innervating the cornea and
conjunctiva. Within the corneal stroma, they form a subepithelial
nerve plexus whose ascending branches ramify extensively to
terminate within the surface epithelial layers. Functionally, sensory
nerves belong to polymodal nociceptor neurons, pure mechano-
nociceptor neurons and cold thermoreceptor neurons. Polymodal
nociceptors are normally silent and respond to chemical,
Fig. 4. Diagram summarizing how ocular inﬂammation of various etiologies or ocular surface drying in DED, provoke variable increases (þ) or decreases () of nerve impulse
activity in polymodal- and mechano-nociceptors and in cold thermoreceptors of the high background, low threshold (HB-LT) and low background, high threshold (LB-HT) types.
Together these changes elicit conscious sensations of different quality, as well as changes in tear ﬂow and in spontaneous and reﬂex blinking.
J.P. Craig et al. / The Ocular Surface 15 (2017) 802e812808mechanical, and thermal stimuli. The inﬂammatory mediators
released during injury sensitize them. The transient receptor po-
tential cation channel subfamily V member 1 (TRPV1) is important
for sensory transduction and sensitization of polymodal noci-
ceptors. Pure mechano-nociceptors are also silent at rest and
respond only to mechanical forces perhaps through piezo2 and
other non-identiﬁed transducing channels. Cold thermoreceptors
continuously discharge nerve impulses at the normal eye surface
temperature, respectively augmenting or decreasing the basal
ﬁring frequency with cooling or warming. TRPM8 is their main cold
transducing channel and is also sensitive to osmolarity increases.
Inter-blink tear evaporation causes discrete cooling of the ocular
surface and tear osmolarity rises, thereby augmenting basal activity
of cold thermoreceptors. This is consistent with the hypothesis that
cold-sensitive ﬁbers contribute to the reﬂex control of basal tear
production and blinking.
The TG neurons from the ocular surface project primarily into
two spatially discrete regions within the trigeminal brain stem
nuclear complex: the transition region between caudal Vi and Vc
(ViVc transition) and at the Vc/upper cervical cord junction (VcC1
region). Evidence suggests that the VcC1 region plays a dominant
role in sensory-discriminative aspects of ocular pain. ViVc transi-
tion neurons are excited by bright light and are activated by
changes in themoisture status of the ocular surface. Ocular neurons
at the ViVc transition project to brain regions that control lacri-
mation (superior salivatory nucleus) and blinking (facial motor
nucleus) as well as to the sensory thalamus. Thus, it is suggested
that ocular neurons at the ViVc transition play a signiﬁcant role in
maintaining ocular surface homeostasis.
The secretory activity of the main lacrimal gland is regulated
by autonomic sympathetic and parasympathetic nerves whose
activity is regulated by reﬂex inﬂuences from sensory neurons
supplying the ocular surface. Parasympathetic innervation is more
extensive. Very little is known about the neural control of acces-
sory lacrimal glands, but it appears to be similar to the main
lacrimal gland. While nerves are present around the meibomian
glands, there are no studies examining the role of sensory or
autonomic nerves and their neurotransmitters in regulating the
holocrine secretion of the meibomian gland. Activation of sensory
nerves supplying the rat cornea evokes goblet cell mucous
secretion; however efferent nerve type(s) involved in this reﬂex
response remain to be established. Several non-neural processes
regulate the release of mucins from stratiﬁed squamous cells, butto date no regulatory role for nerves or neurotransmitters has
been identiﬁed.
In addition to regulation of tear production, ocular surface
nerves mediating sensations contribute to blinking behavior
(Fig. 4). It has been suggested that spontaneous blinking is main-
tained, at least in part by the continuous nerve impulse ﬁring of eye
surface cold thermoreceptors, an effect likely mediated by the
connections of TG neurons with brainstem Vi/Vc neurons which in
turn project to the motor neurons of the facial nerve (Cranial nerve
VII). Nociceptor sensory input, projecting to neurons at the VcC1
region, initiates reﬂex blinking through their projections to ViVc
transition neurons, and sets blink amplitude and peak velocity of
corneal reﬂex blinks.
In DED, reduced tear secretion leaves the corneal epithelium
exposed to adverse environmental conditions and often leads to
variable levels of inﬂammation and to peripheral nerve terminal
damage. Inﬂammation causes sensitization of polymodal noci-
ceptors and mechano-nociceptors, while it depresses cold ther-
moreceptor activity. However, in experimental DED the
sensitization of nociceptor ﬁbers is discrete and the most promi-
nent nerve disturbance is the sustained, abnormal increase in cold
thermoreceptor nerve activity that occurs in parallel with
morphological changes in corneal innervation. This suggests that
dryness-induced nerve damage dominates over inﬂammation,
causing abnormal activity primarily in cold terminals. In parallel
with these changes in peripheral nerve activity, brainstem ocular
neurons at both ViVc and VcC1 regions display enhanced
responsiveness.8. Iatrogenic dry eye [10]
As reported by the TFOS DEWS II Iatrogenic Dry Eye Subcom-
mittee, DED can be caused by a variety of iatrogenic interventions,
including topical and systemic drugs, the use of contact lenses, and
ophthalmic surgical and non-surgical procedures.
Topical medications that cause DED (Table 2) interact with the
ocular surface by exerting allergic, toxic and immuno-inﬂammatory
effects. Preservatives, such as benzalkonium chloride, may cause or
aggravate DED through their toxic and proinﬂammatory effects, as
well as detergent tensioactive properties. Moreover, a great variety
of systemic drugs, such as vasodilators, sulfonylureas, anxiolytics,
antidepressants, antihistamines, and those listed in Table 3, may
also induce DED secondary to decreased tear production, altered
Table 2
Examples of topical treatments that may induce or worsen DED.
Compounds Examples
Adrenergic agonists Apraclonidine, Brimonidine, Dipivefrin
Anti-allergics Emedastine, Olopatadine
Anti-virals Aciclovir, Idoxuridine, Triﬂuridine
bblockers Betaxolol, Carteolol, Levobunolol, Metipranolol, Timolol
Carbonic anhydrase inhibitors Brinzolamide, Dorzolamide
Cholinergic agonists Pilocarpine, Ecothiopate
Decongestants Naphazoline, Tetryzoline
Miotics Dapiprazole
Mydriatics & cyclopegics Cyclopentolate, Tropicamide, Hydroxyamfetamine
Prostaglandins Bimatoprost, Latanoprost, Travoprost, Unoprostone
Topical and local anesthetics Cocaine, Proxymetacaine, Tetracaine
Topical ocular non-steroidal anti-inﬂammatory drugs Bromfenac, Diclofenac, Ketorolac, Nepafenac
Table 3
Known or suspected systemic medications causing, contributing to, or aggravating
DED.
Category Subcategory
Analgesic Antirheumatic
Cannabinoid
Opioid
Anesthesia
Anticholinergic (antimuscarinic) Antiarrythmic/Bronchodilating
Antihistamine
Antidepressant
Anti-Parkinson's
Antipsychotic
Antispasmodic
Decongestant
Antihypertensive Adrenergic blocking
NaþCl- Co-transporter (diuretic)
Antileprosy
Antimalarial
Antineoplastic
Anxiolytic/hypnotic
Chelator/Calcium Regulator
Depressant
Herbal and Vitamins
Hormonal Antiandrogen/Estrogen replacement
Neurotoxin
Sedative
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glands, or direct irritation effect through secretion into the tears.
DED in contact lens wearers has been identiﬁed as an ongoing
issue for many patients. The use of contact lenses can either induce
or be associated with DED. Biophysical changes to the tear ﬁlm in
contact lens wearers with DED include a thinner, patchy lipid layer;
tear ﬁlm instability; lower basal tear turnover rate; and decreased
tear meniscus volume.
Surgical procedures such as corneal refractive surgery and ker-
atoplasty may cause or aggravate DED through mechanisms
intrinsic to the procedure (i.e. corneal nerve transection) or even by
the use of postoperative topical drugs. Cataract surgery, lid sur-
geries, botulinum toxin application and cosmetic procedures are
also considered risk factors for iatrogenic DED, which can be the
cause of patient dissatisfaction, visual disturbance and poor surgi-
cal outcomes.
Future directions to address iatrogenic DED include more in
depth epidemiological studies about the risk factors, development
of less toxic medications and preservatives, as well as new tech-
niques for less invasive eye surgeries. Novel research into detecting
early DED prior to ocular surgery, determining the beneﬁts ofprophylactic treatment, as well as efforts to establish appropriate
therapeutics, and improving attempts to regulate and oversee
medications, preservatives and procedures should be considered.9. Diagnostic methodology [11]
The TFOS DEWS II Diagnostic Methodology Subcommittee
examined the research evidence for tests to quantify patient
symptoms, visual disturbance, tear ﬁlm stability, osmolarity, tear
volume, ocular surface damage, inﬂammation of the ocular surface
and eyelid signs (such as MGD), and recommended the key diag-
nostic tests and techniques. While many tests have been suggested
to be diagnostic of DED, their sensitivity and speciﬁcity is highly
dependent on the inclusion criteria and severity of the DED group
and the population examined. The Subcommittee made the
following recommendations to represent the best available evi-
dence to diagnose and subtype DED in a clinical setting. The se-
lection principles were: diagnostic ability; minimal-invasiveness;
objectivity; and clinical applicability.
The recommended tests for the diagnosis of DED and assess-
ment of its severity are presented in Fig. 5 Prior to diagnosis, it is
important to exclude conditions that can mimic DED with a num-
ber of triaging questions (Fig. 5). Such conditions and their differ-
entiating features are outlined in the report. Following this, the Dry
Eye Questionnaire-5 (DEQ-5) or Ocular Surface Disease Index
(OSDI) should be completed to indicate whether a patient might
have DED, and a positive symptom score on either of these ques-
tionnaires should then trigger a more detailed examination for
clinical signs of DED. The presence of any one of three speciﬁed
signs; reduced non-invasive break-up time; elevated or a large
interocular disparity in osmolarity; or ocular surface staining (of
the cornea, conjunctiva or lid margin) in either eye, is considered
representative of disrupted homeostasis, conﬁrming the diagnosis
of DED. If a patient has DED symptoms and their practitioner does
not have access to all these tests, a diagnosis is still possible, based
on a positive result for any one of the markers, but may require
referral for conﬁrmation if the available homeostasis markers are
negative. Guidance on how, and in which order, to conduct these
tests are provided within the report and videos are available on the
TFOS website (www.tearﬁlm.org).
Having conﬁrmed that the condition is DED on the basis of a
positive symptom score and one or more positive homeostatic
marker results, further subtype classiﬁcation tests such as mei-
bography, lipid interferometry and tear volume measurement
should be conducted to determine: 1) where the DED falls on the
spectrum between ADDE and EDE, and 2) the severity of DED, in
order to guide treatment.
Fig. 5. Recommended diagnostic approach for DED. Please see the original report for a complete description of this ﬁgure [11].
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Themanagement of DED is complicated, due to its multifactorial
etiology. Expanding upon the simple belief that “diagnosis pre-
cedes therapy”means that cliniciansmustmake their best efforts to
identify the degree towhich EDE, ADDE and/or other ocular surface
conditions are contributing to the patient's presentation. This
aspect of determining themajor causative factors behind the DED is
critical to appropriate management.
The ultimate aim of DED management is to restore the ho-
meostasis of the ocular surface and tear ﬁlm, through breaking the
vicious cycle of the disease. While certain treatments may be spe-
ciﬁcally indicated for one particular aspect of an individual patient's
condition, a number of therapies might be appropriately recom-
mended in order to treat the multiple aspects of a patient's pre-
sentation with DED. While aiming to identify and treat the primary
source of the disease, the management of DED typically involves
ongoing management to address chronic sequelae, rather than
short-term treatment.
The presented management algorithm is not proposed as a rigidsequential approach to be followed linearly. Instead, it should be
viewed as an organizational tool to help guide initiation of treat-
ment with those interventions most likely to beneﬁt most patients
with DED, and progressing to more advanced and speciﬁc treat-
ments aimed at particular aspects of the DED pathophysiology. On-
going scientiﬁc evidence, as well as risk versus beneﬁt and cost
considerations, will also contribute to decisions made in choosing
between multiple treatment options.
Management algorithms are often constructed to recommend a
sequence of treatments according to the stage of disease, but this
construction is complicated in DED, as the disease often varies from
patient to patient, both in severity and in character. Table 4 lists a
series of management and treatment options that have all been
shown to result in alleviation of presenting DED [12]. Should pa-
tients not respond to a given level of management, or should they
present with more severe DED, the next level of management is
recommended and in some cases the previous therapy may be
continued in addition to any new therapies. In general, manage-
ment approaches begin with conventional, low-risk and easily
accessible patient-applied therapies such as over-the-counter
Table 4
Recommendations for the staged management and treatment of DED.a,b,c
Step 1:
 Education regarding the condition, its management, treatment and prognosis
 Modiﬁcation of local environment
 Education regarding potential dietary modiﬁcations (including oral essential fatty acid supplementation)
 Identiﬁcation and potential modiﬁcation/elimination of offending systemic and topical medications
 Ocular lubricants of various types (if MGD is present, then consider lipid-containing supplements)
 Lid hygiene and warm compresses of various types
Step 2:
If above options are inadequate consider:
 Non-preserved ocular lubricants to minimize preservative-induced toxicity
 Tea tree oil treatment for Demodex (if present)
 Tear conservation
 Punctal occlusion
 Moisture chamber spectacles/goggles
 Overnight treatments (such as ointment or moisture chamber devices)
 In-ofﬁce, physical heating and expression of the meibomian glands (including device-assisted therapies, such as LipiFlow)
 In-ofﬁce intense pulsed light therapy for MGD
 Prescription drugs to manage DEDd
 Topical antibiotic or antibiotic/steroid combination applied to the lid margins for anterior blepharitis (if present)
 Topical corticosteroid (limited-duration)
 Topical secretagogues
 Topical non-glucocorticoid immunomodulatory drugs (such as cyclosporine)
 Topical LFA-1 antagonist drugs (such as liﬁtegrast)
 Oral macrolide or tetracycline antibiotics
Step 3:
If above options are inadequate consider:
 Oral secretagogues
 Autologous/allogeneic serum eye drops
 Therapeutic contact lens options
 Soft bandage lenses
 Rigid scleral lenses
Step 4:
If above options are inadequate consider:
 Topical corticosteroid for longer duration
 Amniotic membrane grafts
 Surgical punctal occlusion
 Other surgical approaches (eg tarsorrhaphy, salivary gland transplantation)
MGD e meibomian gland dysfunction; DED e dry eye disease; This Table was reproduced from Ref. [12].
a Potential variations within the disease spectrum are acknowledged to exist between patients and the management options listed above are not intended to be exclusive.
The severity and etiology of the DED state will dictate the range and number of management options selected from one or more steps.
b One or more options concurrently within each category can be considered within that step of the dry eye disease state. Options within a category are not ranked according
to importance and may be equally valid.
c It should be noted that the evidence available to support the various management options differs and will inevitably be lower for newer management options. Thus, each
treatment option should be considered in accordance with the level of evidence available at the time management is instigated.
d The use of prescription drugs needs to be considered in the context of the individual patient presentation, and the relative level of evidence supporting their use for that
speciﬁc indication, as this group of agents differs widely in mechanism of action.
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therapies for more severe forms of DED. However, it must be un-
derstood that there is signiﬁcant heterogeneity in the DED patient
population. The approach cannot be overly formulaic and these
recommendations may be modiﬁed and overlapped as required by
practitioners based on an individual patient proﬁle.
The expected treatment trial duration before concluding failure
to improve is related both to the individual's response and to the
therapy being considered. Most commonly, treatment effects are
observedwithin one to threemonths, although some therapies (e.g.
cyclosporine A) may take longer.
Overall, the treatment of DED remains something of an art, not
easily lending itself to a rigid, evidence-based algorithm that ac-
commodates all patients with DED symptoms or signs. All eye care
providers who treat patients with DED must exercise their clinical
skills to judge the signiﬁcance of each of the varied pathogenic
processes that may manifest similar subjective complaints and
similar signs of ocular surface dysfunction.11. Clinical trial design [13]
In order to improve the quality of clinical trials, to optimize
resources, and to increase the opportunity for novel therapeutics to
reach patients with DED, the TFOS DEWS II Clinical Trials Sub-
committee made the following recommendations.
First, that studies be conducted consistent with Good Clinical
Practice (GCP). While this may be a daunting task, clinical trialists
should consult colleagues and drug development experts who are
familiar with this system of controls. This includes appropriate
protections for the study subjects. GCP also requires compliance
with appropriate regulatory requirements in the jurisdiction of
study conduct, and may require additional regulatory ﬁlings if the
investigational shipment is prepared and sent from another state or
country.
The Consolidated Standards of Reporting Trials (ConSORT)
statement is useful to review prior to planning and starting a study.
Next, the Subcommittee recommended that the design, treatments,
and sample size be consistent with the investigational treatment,
Fig. 6. TFOS DEWS II™ report.
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example, a crossover or paired-comparison design may be appro-
priate for a comfort study in normal volunteers, but not for a long-
lasting treatment with potential for systemic or contralateral ef-
fects. Also, the dose of a drug or biologic should not only be less
than that whichwas toxic or not tolerated in nonclinical or previous
clinical studies, but must be sufﬁcient, in dose and frequency, to
deliver therapeutic concentrations at the intended site of action.
The duration of treatment, at least for a pivotal study, should also be
consistent with the mechanism of action and time course of effect.
For pivotal studies, sample size is key to the potential validity of the
study.
Outcome measures are critical to determine the efﬁcacy of the
treatment and, if possible, should include minimally invasive
objective metrics that align with the expected mechanism of
action of the treatment. Exploration of new ways to evaluate
DED, such as biomarkers, may lead to improvement in DED
clinical trial design and increased clarity on the efﬁcacy of new
treatments.
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